

Narendranath Epperla

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6327310/narendranath-epperla-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

894
citations

16
h-index

23
g-index

167
ext. papers

1,275
ext. citations

3.8
avg, IF

4.59
L-index

#	Paper	IF	Citations
149	Racial differences in the survival of mantle cell lymphoma patients in the United States.. <i>Hematological Oncology</i> , 2022 ,	1.3	
148	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021 , 138, 455-455	2.2	1
147	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 884-884	2.2	2
146	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021 , 138, 1451-1451	2.2	
145	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021 , 138, 532-532	2.2	
144	Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021 , 138, 93-93 ²		3
143	Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study. <i>Blood</i> , 2021 , 138, 1425-1425	2.2	
142	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 ,		1
141	Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. <i>OncoTargets and Therapy</i> , 2021 , 14, 1797-1805	4.4	6
140	Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. <i>Cancers</i> , 2021 , 13,	6.6	5
139	How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. <i>Blood</i> , 2021 , 138, 520-530	2.2	0
138	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3339-3350	12.9	7
137	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
136	Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States. <i>American Journal of Hematology</i> , 2021 , 96, 816-822	7.1	2
135	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 104	22.4	3
134	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021 , 107, 301-310	3.8	1
133	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021 , 7, 993-1003	13.4	5

132	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021 , 5, 2852-2862	7.8	5
131	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021 , 137, 374-386	2.2	19
130	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 58-66		5
129	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021 , 106, 1932-1942	6.6	8
128	Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). <i>American Journal of Hematology</i> , 2021 , 96, E123-E126	7.1	4
127	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021 , 39, 473-482	1.3	1
126	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021 , 96, 1374-1384	7.1	2
125	Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. <i>Cancer Medicine</i> , 2021 , 10, 7330-7338	4.8	1
124	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021 , 5, 5179-5189	7.8	0
123	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021 , 195, 757-763	4.5	2
122	A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. <i>Current Hematologic Malignancy Reports</i> , 2021 , 16, 19-24	4.4	2
121	Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 247-253	3.1	2
120	What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid. <i>British Journal of Haematology</i> , 2020 , 190, 490-492	4.5	3
119	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020 , 6, 1011-1018	13.4	19
118	Emerging therapies in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 79	22.4	14
117	Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?. <i>Cancer Medicine</i> , 2020 , 9, 5519-5525	4.8	6
116	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020 , 189, 1171-1181	4.5	22
115	Outcomes after stereotactic radiosurgery for CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 465-476	4.8	4

114	Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 47	4.2	3
113	Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
112	Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020 , 136, 31-32	2.2	
111	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020 , 136, 24-26	2.2	
110	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
109	Racial and Ethnic Disparities in the Survival of Patients with Indolent Non-Hodgkin Lymphoma in the United States: A Population-Based Analysis. <i>Blood</i> , 2020 , 136, 3-3	2.2	
108	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020 , 136, 4-6	2.2	
107	Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. <i>Blood</i> , 2020 , 136, 9-9	2.2	
106	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020 , 136, 46-49	2.2	
105	Relative Survival of Patients with Nodal Marginal Zone Lymphoma in the United States: A Population-Based Analysis. <i>Blood</i> , 2020 , 136, 5-6	2.2	1
104	Impact of Primary Site and Era of Diagnosis on Mortality in Patients with Extranodal Marginal Zone Lymphoma in the United States: A Population-Based Study. <i>Blood</i> , 2020 , 136, 44-44	2.2	
103	A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 29-29	2.2	0
102	Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. <i>Blood</i> , 2020 , 136, 2-3	2.2	2
101	Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20064-e20064	2.2	
100	Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8043-8043	2.2	
99	NCMP-12. RAPIDLY PROGRESSIVE NEUROPATHIES AS THE SOLE PRESENTATION OF NEUROLYMPHOMATOSIS. <i>Neuro-Oncology</i> , 2020 , 22, ii125-ii125	1	1
98	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 6187-6195	12.9	3
97	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020 , 4, 47-54	7.8	11

96	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020 , 126, 2279-2287	6.4	6
95	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020 , 136, 35-36	2.2	1
94	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , 2019 , 125, 4417-4425	6.4	8
93	A gene-based recessive diplotype exome scan discovers , a novel hepcidin-regulating iron-metabolism gene. <i>Blood</i> , 2019 , 133, 1888-1898	2.2	12
92	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019 , 3, 1661-1669	7.8	13
91	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019 , 134, 397-397	2.2	3
90	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019 , 134, 402-402	2.2	7
89	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 753-753	2.2	6
88	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3997-3997	2.2	1
87	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3483-3483	2.2	1
86	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019 , 134, 1525-1525	2.2	4
85	HSR19-086: Healthcare Costs and Resource Utilization Associated With Adverse Events Among Hairy Cell Leukemia Patients Treated With Purine Nucleoside Analogs. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, HSR19-086	7.3	
84	Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial. <i>Blood</i> , 2019 , 134, 2853-2853	2.2	2
83	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5891-5891	2.2	
82	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. <i>Blood</i> , 2019 , 134, 1554-1554	2.2	
81	Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 4082-4082	2.2	0
80	Resistance mechanism for ibrutinib in marginal zone lymphoma. <i>Blood Advances</i> , 2019 , 3, 500-502	7.8	11
79	PHASE I DOSE-ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH-RISK NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. <i>Hematological Oncology</i> , 2019 , 37, 528-529	1.3	

78	MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). <i>Hematological Oncology</i> , 2019 , 37, 405-407	1.3	1
77	OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. <i>Hematological Oncology</i> , 2019 , 37, 408-410	1.3	10
76	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 95-102	2	3
75	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. <i>Bone Marrow Transplantation</i> , 2019 , 54, 913-916	4.4	1
74	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 6	22.4	15
73	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2
72	Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?. <i>Annals of Hematology</i> , 2018 , 97, 1727-1729	3	5
71	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018 , 124, 2306-2315	6.4	18
70	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 983-988	4.7	5
69	R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. <i>British Journal of Haematology</i> , 2018 , 180, 534-544	4.5	48
68	Incidence and survival trends in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 181, 703-706	4.5	31
67	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 78-85	4.7	7
66	Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndromes 2018 , 1984-2000		1
65	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. <i>Cancer Management and Research</i> , 2018 , 10, 615-624	3.6	13
64	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2862-2870	1.9	8
63	Recent Survival Trends in Diffuse Large B-Cell Lymphoma (DLBCL)-Did We Make Any Progress Beyond Rituximab?. <i>Blood</i> , 2018 , 132, 4828-4828	2.2	1
62	Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 4185-4185	2.2	1
61	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018 , 132, 4153-4153	2.2	

60	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018 , 132, 2918-2918 ^{2.2}		
59	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. <i>Blood</i> , 2018 , 132, 2305-2305	2.2	1
58	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2018 , 132, 969-969	2.2	
57	Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States. <i>Blood</i> , 2018 , 132, 4833-4833	2.2	
56	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. <i>Blood</i> , 2018 , 132, 4143-4143	2.2	
55	Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. <i>American Journal of Hematology</i> , 2018 , 93, 238-245	7.1	5
54	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018 , 2, 933-940	7.8	23
53	A rash diagnosis: Gemcitabine-associated pseudocellulitis. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 157-160	1.7	10
52	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. <i>Hematological Oncology</i> , 2017 , 35, 528-535	1.3	37
51	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 408-414	2	7
50	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 427-433	4.5	10
49	Indolent lymphomas 2017 , 140-150		
48	Mantle cell lymphoma 2017 , 164-178		
47	Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2017 , 10, 277-284	2.7	18
46	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 117	22.4	17
45	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 305-311.e2	2	4
44	Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. <i>Transfusion</i> , 2017 , 57, 2775-2781	2.9	16
43	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017 , 123, 4411-4418	6.4	19

42	Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017 , 92, E610-E611	7.1	5
41	Medical Management of Pump-Related Thrombosis in Patients with Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. <i>ASAIO Journal</i> , 2017 , 63, 373-385	3.6	35
40	Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. <i>Bone Marrow Transplantation</i> , 2017 , 52, 147-150	4.4	3
39	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43
38	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7541-7541	2.2	
37	Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. <i>Cureus</i> , 2017 , 9, e1262	1.2	0
36	An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2016 , 47, 206-9	1.6	
35	Chemotherapy: Response and Survival Data #99. <i>Journal of Palliative Medicine</i> , 2016 , 19, 1011	2.2	
34	Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016 , 175, 758	4.5	6
33	Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. <i>American Journal of Hematology</i> , 2016 , 91, 644-6	7.1	10
32	Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. <i>American Journal of Hematology</i> , 2016 , 91, E313-4	7.1	15
31	Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah® Witness treated with hemoglobin concentrate complicated by achalasia. <i>Transfusion</i> , 2016 , 56, 1801-6	2.9	7
30	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016 , 128, 1785-1785	2.2	3
29	Outcomes of Grade 3A Follicular Lymphoma: Best Treated As Aggressive or Indolent Lymphoma?. <i>Blood</i> , 2016 , 128, 5328-5328	2.2	1
28	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. <i>Blood</i> , 2016 , 128, 513-513	2.2	
27	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. <i>Blood</i> , 2016 , 128, 103-103	2.2	
26	Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1602-1604	4.4	8
25	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 672-678	2	5

24	Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2016 , 91, 1161-1164	7.1	4
23	Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. <i>Clinical Medicine and Research</i> , 2015 , 13, 85-8	1.4	5
22	An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. <i>BMC Hematology</i> , 2015 , 15, 7	2.5	1
21	Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1393-404	4.4	8
20	Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. <i>SpringerPlus</i> , 2015 , 4, 455		25
19	Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. <i>Clinical Medicine and Research</i> , 2015 , 13, 32-5	1.4	21
18	Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	4
17	Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. <i>World Journal of Transplantation</i> , 2015 , 5, 81-8	2.3	1
16	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 4360-4360	2.2	
15	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 3169-3169	2.2	
14	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. <i>Blood</i> , 2015 , 126, 2711-2711	2.2	
13	Radiographic findings in Waldenström macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): a case report. <i>Skeletal Radiology</i> , 2014 , 43, 381-5	2.7	3
12	An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. <i>Skeletal Radiology</i> , 2014 , 43, 1313-8	2.7	4
11	Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	12
10	Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	3
9	Sjögren syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature. <i>BMC Neurology</i> , 2014 , 14, 200	3.1	27
8	Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. <i>Diagnostic Pathology</i> , 2013 , 8, 192	3	5
7	ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. <i>Clinical Medicine and Research</i> , 2013 , 11, 86-90	1.4	4

6	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 237-8	2.2	10
5	1174. <i>Critical Care Medicine</i> , 2013 , 41, A298-A299	1.4	
4	Non-cardiogenic pulmonary edema complicating electroconvulsive therapy: short review of the pathophysiology and diagnostic approach. <i>Clinical Medicine and Research</i> , 2012 , 10, 131-6	1.4	4
3	Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope. <i>Clinical Medicine and Research</i> , 2012 , 10, 26-31	1.4	10
2	Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy. <i>Clinical Medicine and Research</i> , 2012 , 10, 230-5	1.4	3
1	Sweet [®] syndrome: one disease, multiple faces. <i>Clinical Medicine and Research</i> , 2011 , 9, 134-6	1.4	3